{"filings":[{"id":1593676,"accession_number":"0001104659-26-082947","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-07-13T13:23:16+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tactile Medical signs exclusive distribution deal for ElastiMed's MyoSleeve compression device for VA/DoD patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive U.S. distribution rights for MyoSleeve within VA and DoD systems.","Upfront payment of $3 million to ElastiMed; minimum purchase obligations and marketing commitments.","MyoSleeve is FDA 510(k)-cleared for chronic swelling, lymphedema, and venous insufficiency.","Device uses electroactive polymer technology, battery-powered, no cords or external controller.","Expands Tactile Medical's portfolio to earlier stages of chronic swelling, complementing existing pneumatic devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90694,"accession_number":"0001104659-26-057271","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tactile Systems shareholders approve director removal amendment, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to allow director removal consistent with Delaware law; 14.9M For, 0.9M Against.","All nine director nominees re-elected: Burke, Asbury, Dodd, Huggenberger, King, Pearson, Shafer, Volkart, Washington.","Ratified Grant Thornton LLP as independent auditor for FY2026 with 18.5M For, 0.1M Against, no broker non-votes.","Advisory vote approved named executive officer compensation with 15.4M For, 0.4M Against, 3.0M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90693,"accession_number":"0001104659-26-054869","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.","Net loss $1.8M ($0.08 per share) vs $3.0M loss in Q1 2025; gross margin 76.5% vs 74%.","Adjusted EBITDA $3.7M vs ($0.3M) loss a year ago.","Raised FY2026 revenue guidance to $360-368M (prev $357-365M); adj EBITDA reaffirmed at $49-51M.","Received FDA 510(k) clearance for next-gen AffloVest; acquired LymphaTech for lymphedema diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":75267000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100436,"accession_number":"0001104659-26-024981","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Andrea Pearson to Board of Directors effective March 9, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pearson joins board and serves on Compliance & Reimbursement and Nominating & Corporate Governance committees.","She will receive pro rata RSUs valued at $155,000 and annual cash retainers totaling $60,000 (board plus committees).","Pearson previously scaled DispatchHealth from 2 to 50+ markets, driving 30x revenue increase as Chief Growth Officer.","Board size fixed at nine directors following appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100435,"accession_number":"0001104659-26-016370","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.","Full year 2025 revenue $329.5M (+12% YoY); adjusted EBITDA $44.8M ($37.1M in 2024).","FY2026 guidance: revenue $357-365M (8-11% growth), adjusted EBITDA $49-51M.","Acquired LymphaTech for $6.8M upfront cash plus contingent milestones; adds 3D scanning for lymphedema.","Repaid $26.3M term loan; repurchased $26.5M stock at avg $12.36 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116756,"accession_number":"0001104659-25-105537","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tactile Medical Q3 net income $8.2M, revenue up 17%; raises FY guidance and authorizes $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $85.8M (+17% YoY), net income $8.2M ($0.36 diluted EPS) vs $5.2M ($0.21) in Q3 2024.","Adjusted EBITDA $14.4M vs $10.7M YoY; gross margin 76% vs 75%.","Paid off $24M term loan, refinanced revolver to $40M; cash $66M.","Authorized $25M share buyback program through Nov 2027.","FY 2025 guidance raised: revenue $317-321M (prior $310-315M), adj. EBITDA $38-39.5M (prior $33-35M)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":225928000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133203,"accession_number":"0001558370-25-010096","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Systems Q2 revenue $78.9M (+7.8% YoY); net income $3.2M vs $4.3M; raises low-end of adj EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $78.9M, up 7.8% YoY, ahead of prior expectations; gross margin improved to 75% from 74%.","Net income $3.2M ($0.14 diluted EPS) vs $4.3M ($0.18) in Q2 2024; Adjusted EBITDA $7.7M vs $9.1M.","Airway clearance product line revenue surged 52% YoY; lymphedema product line grew 2%.","FY2025 revenue guidance narrowed to $310-315M (prior $309-315M); adj EBITDA guidance raised to $33-35M (prior $32-34M) but below FY2024 adj EBITDA of $37.1M.","Completed $30M share repurchase program; refinanced credit facility, increased revolver to $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":140173000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149822,"accession_number":"0001104659-25-046813","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 2025 Equity Incentive Plan with 1.85M new shares; all board nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Equity Incentive Plan approved, authorizing up to 1,850,000 new shares of common stock.","All eight director nominees elected, including William Burke, Valerie Asbury, Sheri Dodd, and others.","Say-on-pay approved with 15.7M votes for (96% of votes cast); board sets future advisory votes annually.","Grant Thornton LLP ratified as independent auditor for 2025 with 18.9M votes for.","No further awards will be granted under the 2016 Equity Incentive Plan after approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149821,"accession_number":"0001558370-25-006292","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.","Adjusted EBITDA loss $0.3M vs positive $1.0M in prior-year quarter.","Lymphedema product sales -3% YoY; airway clearance +22% YoY.","FY 2025 revenue guidance lowered to $309-315M (prior $316-322M); EBITDA guidance cut to $32-34M from $35-37M.","Repurchased $10M of stock in Q1; $16.5M remaining under $30M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":61268000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168842,"accession_number":"0001558370-25-001095","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q4 rev $85.6M (+10%), net income $9.7M; guides FY25 rev $316-322M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $85.6M (+10% YoY); gross margin 75.2% vs 72.1% YoY.","Q4 net income $9.7M ($0.40 diluted EPS) vs $8.2M ($0.35) YoY.","FY2024 revenue $293.0M (+7%); net income $17.0M vs $28.5M in 2023.","Cash $94.4M at year-end, up from $61.0M; $26.5M remaining share repurchase authorization.","FY2025 revenue guidance $316-322M (8-10% growth); adjusted EBITDA $35-37M vs $37.1M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":292984000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168841,"accession_number":"0001104659-25-002876","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Laura King to Board of Directors effective Jan 13, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura King elected to Board; serves on Audit and Compliance & Reimbursement Committees.","King brings 22-year GE Healthcare tenure as President & CEO of Global Interventional Business.","Initial RSU grant valued at pro rata portion of $145,000, vesting earlier of one year or 2025 annual meeting.","Annual cash retainers: $50,000 board, $10,000 audit committee, $5,000 compliance committee.","King also co-founder & CEO of BiaCure; formerly led NeuWave Medical (acquired by J&J)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185956,"accession_number":"0001558370-24-014254","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.","Net income $5.2M ($0.21 diluted) vs $22.3M in Q3 2023; adjusted EBITDA $10.7M vs $7.7M.","Gross margin improved to 75.0% from 70.9%; operating expenses up 16%.","FY2024 revenue guidance narrowed to $292-295M (prior $293-298M; growth 6-8%).","Board authorized up to $30M share repurchase program through Oct 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":207399000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202527,"accession_number":"0001558370-24-010853","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.","Net income of $4.3M ($0.18 diluted EPS) vs net loss of $0.1M in Q2 2023; adjusted EBITDA $9.1M.","Full-year 2024 revenue guidance lowered to $293-298M (7-9% growth) from prior $300-305M (9-11%).","Appointed Sheri Dodd as President and CEO effective July 1, 2024; received 510(k) clearance for Nimbl system."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":134306000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202526,"accession_number":"0001104659-24-078098","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tactile Systems settles shareholder derivative lawsuit, agrees to governance reforms and $0.5M fee payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Enters Stipulation of Settlement in derivative lawsuit Weaver v. Moen, dated June 6, 2024.","Agrees to adopt and maintain corporate governance reforms; no admission of liability.","Will pay approximately $0.5 million in attorneys' fees and expenses; service awards up to $7,500 each.","Settlement hearing set for August 28, 2024 before Judge Gregory B. Williams in Delaware District Court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218670,"accession_number":"0001104659-24-059336","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tactile Systems stockholders approve officer exculpation amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Valerie Asbury with 17.8M votes for, 442k withheld.","Ratification of Grant Thornton LLP as independent auditor for 2024 passed with 20.7M for.","Advisory say-on-pay passed with 17.8M for, 419k against, 22.5k abstain.","Amendment to certificate of incorporation allowing officer exculpation approved (17.3M for, 913k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218669,"accession_number":"0001558370-24-006794","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TCMD Q1 revenue up 4% to $61.1M, net loss $2.2M; reaffirms FY2024 outlook; CEO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $61.1M (+4% YoY); lymphedema +5%, airway clearance -4%.","Net loss $2.2M ($0.09/diluted share) vs $1.9M loss in Q1 2023; adjusted EBITDA $1.0M vs $0.5M.","Reaffirmed FY2024 revenue guidance $300M-$305M (9-11% growth).","CEO Dan Reuvers retiring July 1, 2024; Sheri Dodd appointed President and CEO effective same date.","Cash $60.7M, debt $28.5M; completed enrollment of 235-patient Flexitouch Plus trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":61088000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218668,"accession_number":"0001104659-24-050589","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical CEO transition and preliminary Q1 revenue ~$61M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Dan Reuvers to retire June 30, 2024; Sheri Dodd appointed CEO effective July 1, 2024.","Sheri Dodd most recently President of Medtronic Canada; has served on TCMD board since 2021.","Preliminary Q1 2024 revenue ~$61M, up from $58.8M in Q1 2023.","Dodd's initial annual base salary $650K, target bonus 90%, equity awards $1.725M (RSUs+PSUs).","Reuvers to remain as advisor through March 2025 and on board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238564,"accession_number":"0001558370-24-001329","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q4 net income up 77% to $8.2M; FY revenue $274.4M (+11%); introduces FY24 outlook $300-305M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $77.7M (+5% YoY); net income $8.2M (+77%); diluted EPS $0.35 vs $0.23.","FY2023 revenue $274.4M (+11% YoY); net income $28.5M (vs net loss $17.9M in 2022); diluted EPS $1.23.","FY2023 adjusted EBITDA $29.7M (+62% YoY); operating cash flow $35.9M (+$30.6M); debt down to $29.3M.","FY2024 revenue guidance $300M-$305M (9-11% growth); cash $61.0M; completed $16.8M revolver retirement.","Over 77,000 patients treated; introduced Entre Plus and Flexitouch ComfortEase upper extremity garments."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":274423000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256081,"accession_number":"0001558370-23-017786","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q3 revenue $69.6M (+7% YoY); net income $22.3M vs loss; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $69.6M, up 7% YoY; lymphedema +15%, airway clearance -36%.","Net income $22.3M ($0.94 diluted EPS) vs loss of $2.3M ($0.11 loss) in Q3 2022.","Adjusted EBITDA $7.7M vs $7.2M; operating income $8.0M vs loss of $1.6M.","FY2023 revenue guidance narrowed to $273-277M from $274-278M, ~11-12% growth.","Sherri Ferstler appointed SVP Sales; Vindell Washington, M.D. added to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":196771000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256080,"accession_number":"0001104659-23-105951","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Dr. Vindell Washington to board of directors effective Oct 2, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Vindell Washington, M.D. to board effective Oct 2, 2023; brings 30+ years healthcare experience.","Will chair Compliance & Reimbursement Committee and serve on Nominating & Corporate Governance Committee.","Initial pro rata RSU grant of $145K plus annual cash retainers of $50K (board), $10K (committee chair), $5K (committee member)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273483,"accession_number":"0001558370-23-013632","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q2 revenue $68.3M (+15% YoY); narrows net loss to $0.1M; raises FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $68.3M (+15% YoY); lymphedema +16%, airway clearance +4%.","Net loss $0.1M ($0.00/diluted) vs loss $4.6M ($0.23/diluted) in Q2 2022.","Adjusted EBITDA $6.1M, up from $1.7M; cash $63.2M; debt $47.5M.","FY23 revenue guidance raised to $274M-$278M (prev $271M-$275M, +11%-13% YoY).","Sherri Ferstler appointed SVP of Sales (Jul 31); credit agreement amended to extend maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":127185000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273482,"accession_number":"0001104659-23-081829","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Sherri Ferstler SVP Sales; Eric Pauls resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Pauls resigns as SVP Sales effective July 28, 2023.","Sherri Ferstler appointed SVP Sales effective July 31, 2023.","Ferstler previously VP North America at Johnson & Johnson Vision, leading a team of over 325.","Ferstler brings over 25 years of healthcare sales leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290438,"accession_number":"0001104659-23-057737","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tactile Systems stockholders elect all seven director nominees at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Valerie L. Asbury, William W. Burke, Sheri L. Dodd, Raymond O. Huggenberger, Daniel L. Reuvers, D. Brent Shafer, and Carmen B. Volkart elected to one-year terms.","Grant Thornton LLP ratified as independent auditor for FY2023 with 17,856,366 votes for.","Advisory vote on named executive officer compensation approved with 13,657,526 votes for.","Broker non-votes of 3,627,764 recorded on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290437,"accession_number":"0001558370-23-008560","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue up 23% to $58.8M; raises FY2023 guidance to $271-275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $58.8M (+23% YoY); net loss narrowed to $1.9M ($0.09 diluted) from $15.6M loss ($0.78).","Lymphedema revenue +22%, airway clearance +24%; gross margin 70.5%.","Adjusted EBITDA turned positive to $0.5M from ($2.6M) loss in Q1 2022.","FY2023 revenue guidance raised to $271-275M (prior $269-273M), growth ~10-11.5%.","Closed public equity offering raising $34.6M net; appointed Elaine Birkemeyer as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":58846000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311328,"accession_number":"0001104659-23-032091","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Elaine Birkemeyer as CFO, effective March 20, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Birkemeyer succeeds retiring CFO Brent Moen; brings 26 years of finance experience from UnitedHealth Group and Best Buy.","Initial base salary of $400,000 with target annual cash bonus of 55% of base salary.","Equity awards: $250,000 sign-on RSUs (3-year vest) and $600,000 annual award (60% RSUs, 40% PSUs).","Most recently served as CFO of UnitedHealth's Optum Care Solutions; previously CFO of Rally Health.","Appointment effective March 20, 2023; company reiterates commitment to long-term profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311327,"accession_number":"0001104659-23-026756","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tactile Medical prices $32.5M public offering of 2.5M shares at $13.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $32.5M from 2,500,000 shares at $13.00 per share.","Underwriter granted 30-day option to purchase up to 375,000 additional shares.","Net proceeds to expand commercial activities, fund milestones, support new product development, and for working capital.","Offering expected to close on or about February 28, 2023.","William Blair & Company acting as sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311326,"accession_number":"0001558370-23-001566","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical Q4 revenue up 20% to $73.9M; CFO Brent Moen to retire in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $73.9M (+20% YoY); lymphedema +14%, airway clearance +90%.","Q4 GAAP net income $4.6M ($0.23/diluted) vs net loss of $7.5M in Q4 2021.","Full year 2022 revenue $246.8M (+19% YoY); net loss $17.9M vs $11.8M in 2021.","FY 2023 revenue guidance $269M-$273M (9-11% growth); reaffirms long-term goals.","CFO Brent Moen to retire in 2023; board initiated successor search; Moen stays until appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":246785000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311325,"accession_number":"0001104659-23-001174","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Carmen Volkart to Board of Directors effective Jan 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carmen Volkart elected to board; board size fixed at eight directors as of Jan 5, 2023.","She will serve on the Audit Committee and Compliance and Reimbursement Committee.","Initial RSU grant of pro-rata $145,000 value plus annual cash retainers of $50,000 (board), $10,000 (audit), $5,000 (compliance).","Volkart is CFO of NatureWorks LLC; previously CFO of NxThera, Tornier, and executive roles at medical device firms.","Press release issued Jan 5, 2023 announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329935,"accession_number":"0001104659-22-129888","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tactile Systems amends bylaws to implement Rule 14a-19 director nomination procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders must certify compliance with Rule 14a-19 and provide evidence five business days before the meeting.","If a stockholder fails to comply with Rule 14a-19, its nominations are void and proxies for those nominees disregarded.","White proxy cards reserved for Board of Directors only; rules for stockholder meeting conduct updated.","Amendments conform stockholder list provisions to recent Delaware General Corporation Law changes.","Bylaws effective December 19, 2022; other technical, clarifying, and conforming changes included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329934,"accession_number":"0001558370-22-018250","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tactile Systems posts updated November 2022 investor presentation; no new financial data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation filed as Exhibit 99.1; posted on company website.","Presentation contains forward-looking statements but no revised guidance or specific financial metrics.","No material changes to business outlook or strategy disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329933,"accession_number":"0001558370-22-016619","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q3 revenue up 24% to $65.3M; raises FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $65.3M (+24% YoY); net loss $2.3M ($0.11/sh) vs loss $3.4M ($0.17) a year ago.","Non-GAAP net income $1.9M vs non-GAAP loss $1.6M; Adjusted EBITDA $7.2M vs $4.1M.","Airway clearance revenue $11.0M (incl. AffloVest); lymphedema revenue up 5%.","Raises FY2022 revenue guidance to $242-245M (16-18% growth) from prior $238-242M.","Gross margin improved to 71.7% from 70.4%; cash $23.4M, debt $49.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":172885000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347503,"accession_number":"0001558370-22-011455","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q2 revenue $59.6M (+17% YoY); raises FY22 revenue guidance to $238-242M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.6M ($0.23/share) vs net income $1.3M ($0.07) in Q2 2021; adjusted EBITDA $1.7M vs $4.1M.","Airway clearance products added $8.0M revenue; lymphedema sales up 1% YoY.","Full-year 2022 revenue guidance raised to $238-242M from prior $235-240M (14-16% growth).","Operating loss widened to $4.1M from $0.1M; cash $23.4M, debt $50.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":107623000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363972,"accession_number":"0001104659-22-058245","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tactile Systems stockholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Valerie L. Asbury, William W. Burke, Sheri L. Dodd, Raymond O. Huggenberger, Deepti Jain, Daniel L. Reuvers, D. Brent Shafer.","Ratification of Grant Thornton LLP as independent auditor for 2022 approved: 17,198,874 for, 115,034 against, 11,825 abstentions.","Advisory vote on executive compensation approved: 15,127,920 for, 403,898 against, 35,644 abstentions, 1,758,271 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363971,"accession_number":"0001558370-22-006628","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue $48.0M (+12% YoY); net loss $15.6M vs $2.3M loss YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.0M (+12% YoY); net loss $15.6M ($0.78 diluted EPS) vs $2.3M ($0.12) in Q1 2021.","Operating loss $14.9M vs $4.1M YoY; non-GAAP operating loss $5.4M vs $3.1M.","Adjusted EBITDA loss $2.6M vs $7K loss YoY.","Reaffirmed FY2022 revenue guidance $235M-$240M (13-15% growth).","Airway clearance product line contributed $7.3M revenue; lymphedema product line declined 5%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":47978000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383700,"accession_number":"0001558370-22-001579","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q4 rev $61.7M (+4% YoY); net loss $7.5M; FY 2022 guidance $235-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $61.7M (+4% YoY); full year 2021 revenue $208.1M (+11% YoY).","Q4 net loss $7.5M ($0.38 loss per share) vs net income $12.1M ($0.61 EPS) in Q4 2020.","Adjusted EBITDA Q4 $9.5M vs $10.8M prior year; full year $17.7M vs $16.0M.","FY 2022 revenue guidance $235-240M (13-15% growth) with Omicron and staffing headwinds expected in H1.","Qui tam lawsuit dismissed with no damages; board appointed Valerie Asbury and D. Brent Shafer in Jan 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":208057000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383699,"accession_number":"0001104659-22-025350","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tactile Medical announces qui tam lawsuit against it dropped and dismissed without payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Competitor-filed qui tam lawsuit challenging patient/physician education programs dismissed by federal judge in Texas.","Tactile Medical will pay no damages, penalties, attorney fees or other compensation.","Company also dismissed its remaining counterclaims in the case.","CEO Dan Reuvers states dismissal validates confidence in business practices and allows focus on therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383698,"accession_number":"0001104659-22-001452","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Valerie Asbury and D. Brent Shafer to board; three directors to retire at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Valerie Asbury (CEO of LifeScan) and D. Brent Shafer (ex-Cerner CEO) join board effective Jan 5, 2022.","Asbury appointed to Audit and Compliance & Reimbursement Committees; Shafer to Audit, Compensation & Organization, and Nominating & Governance Committees.","Directors Richard Nigon, Kevin Roche, and Peter Soderberg will not stand for re-election at the 2022 annual meeting but serve until term ends.","Each new director receives prorated RSU grant of $130,000 value, vesting on earlier of one year or 2022 annual meeting.","Cash retainers: $50,000 annual board retainer plus committee fees ($5,000-$10,000 per committee)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401527,"accession_number":"0001558370-21-015016","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q3 revenue $52.5M (+7% YoY), net loss $3.4M; cuts FY2021 guidance to $203.5-206M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $52.5M (+7% YoY); net loss $3.4M ($0.17/share) vs net income $2.4M ($0.12) in Q3 2020.","Non-GAAP net loss $1.6M; Adjusted EBITDA $4.1M, down from $6.2M a year ago.","FY2021 revenue guidance cut to $203.5-206.0M (9-10% growth) from prior $216.3-224.5M (16-20%), citing Delta variant and labor shortages.","Acquired AffloVest respiratory therapy on Sept 8, funded with $30M term loan and $25M revolver draw; AffloVest added $0.9M revenue in Q3.","Cash $22.4M, total debt $55.0M under credit agreement as of Sept 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":146329000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420478,"accession_number":"0001104659-21-113788","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Tactile Medical acquires AffloVest respiratory therapy business for $80M cash plus up to $20M earn-outs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AffloVest HFCWO vest business from International Biophysics Corp for $80M cash, with up to $20M in earn-outs based on 12-month revenue targets.","Financed with $55M in borrowings ($30M term loan + $25M revolver draw) under amended Wells Fargo credit facility; cash on hand also used.","AffloVest 2021 revenue expected ~$17M; deal to add $5-5.5M revenue from Sept 8 to Dec 31, 2021.","Transaction aligns with 20%+ revenue growth goal, gross margins above 70%, and expanding adjusted EBITDA margins.","Net leverage expected ~1.4x at year-end 2021 and <1.0x at year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420477,"accession_number":"0001558370-21-009802","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q2 revenue up 45% to $51.1M, net income $1.3M; raises FY guidance low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $51.1M (+45% YoY); net income $1.3M vs loss of $13.9M; diluted EPS $0.07 vs loss of $0.72.","Adjusted EBITDA $4.1M vs loss of $0.7M; operating loss narrowed to $0.1M from $8.0M.","Updated FY2021 revenue guidance: $216.3M–$224.5M (growth 16%–20%), low end raised from prior $215.3M.","Appointed Eric Pauls as SVP of Sales effective May 1, succeeding Bryan Rishe.","Restated credit facility with Wells Fargo: $25M revolving with $30M accordion (up to $55M), replacing $10M facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":93832000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}